Scotiabank sets a USD 305.00 target for Johnson & Johnson stock
Published on 10/27/2026 at 11:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and earnings
- Scotiabank set a USD 305.00 target on October 26, 2026.
- Third-quarter sales increased 5.90 percent year over year on October 13, 2026.
- Johnson & Johnson stock trades at EUR 239.15 at 11:19 a.m. CEST at Lang & Schwarz on October 27, 2026, 0.82 percent above the Xetra close of October 26, 2026.
- Full-year adjusted earnings per share guidance stands at USD 11.05-11.15 for 2026.
Johnson & Johnson stock has a new USD 305.00 price target from Scotiabank, which maintained its Buy rating on October 26, 2026. At Lang & Schwarz, the stock was trading at EUR 239.15 on October 27, 2026 at 11:19 a.m. CEST, up 0.82 percent versus the Xetra close of October 26, 2026 at EUR 237.20.
Target reflects a divided view
According to Business Insider, Scotiabank analyst Louise Chen kept the Buy rating and set the USD 305.00 target on October 26, 2026. The target sits above the euro quotation, but the currencies are different and the figures are not directly comparable.
That view faces a clear counterpoint. MarketBeat reported that Erste Group Bank cut its rating from Buy to Hold on October 21, 2026 and reduced its fiscal 2027 earnings-per-share forecast from USD 12.65 to USD 11.46.
What does the target change?
The latest quarterly figures explain why analysts remain split. In the third quarter of 2026, Johnson & Johnson reported sales of USD 25.40 billion, an increase of 5.90 percent from the third quarter of 2025, according to Johnson & Johnson. Innovative Medicine sales grew 7.70 percent to USD 16.76 billion, while MedTech sales rose 2.50 percent to USD 8.64 billion.
Three dated developments
On October 13, 2026, Johnson & Johnson reported third-quarter sales of USD 25.40 billion and raised adjusted 2026 earnings-per-share guidance to USD 11.05-11.15. On October 21, 2026, Erste Group Bank cut its rating to Hold and lowered its fiscal 2027 forecast to USD 11.46. On October 26, 2026, Scotiabank maintained Buy and set a USD 305.00 target.
Dates and trading levels
The October 13, 2026 earnings release remains the latest reported results date, while the October 26, 2026 Scotiabank note is the latest analyst event. The euro quotation is EUR 4.00 below the 52-week high of EUR 243.15, a 1.65 percent gap calculated from the high.
Stock trades above Xetra close
Johnson & Johnson combines a 5.90 percent quarterly sales increase with adjusted earnings guidance of USD 11.05-11.15 for fiscal 2026. The 2.50 percent MedTech increase was slower than Innovative Medicine's 7.70 percent growth, leaving segment execution central to the valuation debate. The stock was trading at EUR 239.15 at Lang & Schwarz on October 27, 2026 at 11:19 a.m. CEST, 0.82 percent above the Xetra close of October 26, 2026 at EUR 237.20. The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.
Johnson & Johnson stock facts
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 27, 2026, 11:19 a.m. CEST): EUR 239.15
- Change versus Xetra close: plus 0.82 percent
- Xetra close (October 26, 2026): EUR 237.20
- Market capitalization: EUR 575.0 billion (as of October 27, 2026)
- 52-week range: EUR 158.56-243.15 (as of October 27, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Index membership: S&P 500
Market context: Market report S&P 500.
